Larazotide, BPC-157, TB-500, GHK-Cu, and KPV: Performance Peptides Explained

What Is Larazotide and How Does It Work?

Larazotide acetate (AT-1001) is a synthetic octapeptide that acts locally inside the small intestine to reassemble tight-junction proteins, specifically occludin and zonulin-regulated claudin complexes, without entering systemic circulation in meaningful amounts. It does not suppress the immune system. Instead, it blocks the signaling cascade that gliadin and other luminal antigens use to open paracellular spaces, which are the microscopic gaps between enterocytes that allow partially digested proteins to contact the lamina propria.

The zonulin pathway is the best-characterized mechanism of increased intestinal permeability in humans. A 2003 paper by Fasano et al. in the Journal of Clinical Investigation identified zonulin as the only known physiologic modulator of intestinal tight junctions [1]. Larazotide was engineered to compete at the zonulin receptor before that signal can widen tight junctions.

In the ACT-CeD trial (N=342), adults with celiac disease on a gluten-free diet who still experienced symptoms were randomized to larazotide 0.5 mg three times daily or placebo. The 0.5 mg arm showed a statistically significant reduction in the Celiac Disease Gastrointestinal Symptom Rating Scale (CeD-GSRS) score compared with placebo (P<0.001) at 12 weeks [2]. Body weight, diarrhea frequency, and bloating all improved more in the larazotide group. The compound was well tolerated, with headache as the only adverse event reported at a rate above placebo (9% vs. 4%).

Beyond celiac disease, early research suggests larazotide may reduce gut permeability in non-celiac conditions where zonulin is elevated, including type 1 diabetes and irritable bowel syndrome. A 2015 pilot (N=18) published in Alimentary Pharmacology and Therapeutics showed that 12 weeks of larazotide at 0.25 mg three times daily reduced urinary lactulose/mannitol ratios in patients with active Crohn's disease [3]. That ratio is a validated biomarker for paracellular permeability. The effect size was modest (mean ratio dropped from 0.042 to 0.031), but the directional signal justifies further controlled trials.

Current regulatory status: larazotide has received FDA Breakthrough Therapy designation for celiac disease, but no NDA has been approved as of mid-2025. Prescribing it outside a trial requires a compounded formulation and falls under physician discretion [4].

BPC-157: Tissue Repair From the Stomach Up

BPC-157, full name Body Protection Compound-157, is a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from a protein in human gastric juice. It is not a fragment of a hormone. Its primary documented actions include acceleration of angiogenesis, upregulation of growth hormone receptor expression in tendon fibroblasts, and modulation of the NO-system and dopamine system.

Rodent studies dominate the published literature. A 2010 paper in the Journal of Physiology and Pharmacology by Sikiric et al. showed that BPC-157 at 10 mcg/kg intraperitoneally accelerated Achilles tendon healing by 40% compared with saline controls at the four-week mark, measured by breaking-strength tensiometry [5]. A 2013 study in PLOS ONE (N=36 rats) documented that the same dose reduced gastric ulcer area by 82% versus controls after seven days [6].

Human data is sparse. One open-label pilot (N=12) published in a regional gastroenterology journal reported symptom improvement in patients with refractory inflammatory bowel disease who received oral BPC-157 at 250 mcg twice daily for eight weeks, but the study lacked a control arm and used subjective endpoints [7]. No Phase 2 or Phase 3 randomized controlled trial in humans has been completed.

Typical compounded protocols used in clinical practice range from 250 to 500 mcg subcutaneously once daily for musculoskeletal indications, or 250 mcg orally twice daily for GI indications. The half-life after subcutaneous injection is estimated at four to six hours based on pharmacokinetic modeling from animal data. Because no human pharmacokinetic study has been published, dose selection remains empirical.

Safety signals from animal literature are generally reassuring. No oncogenic signal has appeared in rodent studies running up to 90 days, and no significant organ toxicity was observed at doses up to 100 mcg/kg [5]. That does not constitute a clean human safety dossier. Patients interested in BPC-157 should have baseline labs including CMP, CBC, and CRP before starting.

TB-500: The Thymosin Beta-4 Fragment

TB-500 is a synthetic analogue of the actin-sequestering protein thymosin beta-4 (Tb4), specifically mimicking the region spanning amino acids 17 through 23 (the LKKTET sequence). This hexapeptide region is responsible for most of Tb4's documented cell migration and anti-inflammatory activity. The full Tb4 protein is 43 amino acids; TB-500 offers the biologically active core at a fraction of the molecular weight.

Tb4 is among the most abundant intracellular peptides in mammalian tissue, present at concentrations up to 0.5 mM in platelets. After tissue injury, Tb4 is released and binds G-actin monomers, which prevents actin polymerization at wound edges and allows cell migration into the defect. A 2004 paper by Malinda et al. in FASEB Journal established that Tb4 at 50 ng/mL increased dermal fibroblast migration by 3.4-fold compared with vehicle in a scratch-assay model [8].

The most cited human-adjacent evidence involves corneal wound healing. A randomized vehicle-controlled trial (N=72) tested Tb4 eye drops (0.1%) in patients with neurotrophic keratopathy and found complete corneal healing in 69% of the Tb4 group versus 35% of the vehicle group at eight weeks (P<0.001) [9]. This trial used the full Tb4 protein, not the TB-500 fragment, but the LKKTET region is required for migration-promoting activity, so the finding is mechanistically relevant.

No human RCT of injectable TB-500 has been published. Compounded protocols typically range from 2 to 5 mg subcutaneously twice weekly for four to eight weeks, based on extrapolation from animal studies using 0.5 to 2 mg/kg. Anecdotally, athletes report use for tendon and ligament injuries, though no controlled evidence supports this in humans.

TB-500 is not approved by the FDA, WADA classifies thymosin beta-4 peptides as prohibited substances under Section S2 (Peptide Hormones, Growth Factors, Related Substances), and athletes subject to anti-doping testing should not use it [10].

GHK-Cu: Copper Peptide for Collagen and Beyond

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex first isolated from human plasma in 1973 by Pickart and Thaler. Plasma concentrations of GHK decline from roughly 200 ng/mL at age 20 to approximately 80 ng/mL at age 60, a trajectory that has been proposed, though not proven, to contribute to age-related declines in wound healing capacity [11].

The compound binds copper(II) ions with high affinity (dissociation constant approximately 10^-14 mol/L) and delivers bioavailable copper to enzymes including lysyl oxidase, which crosslinks collagen and elastin, and superoxide dismutase, which quenches reactive oxygen species. A 2015 review by Pickart et al. in Biomolecules catalogued that GHK-Cu modulates expression of at least 31 genes associated with tissue remodeling, including upregulation of MMP-2, MMP-9, VEGF, and TIMP-1 [11]. The dual action of stimulating matrix metalloproteinases while also upregulating their inhibitor TIMP-1 produces a controlled remodeling environment rather than unchecked matrix degradation.

Clinical evidence for topical GHK-Cu is more developed than for injectable forms. A double-blind vehicle-controlled trial (N=67) published in Archives of Gerontology and Geriatrics found that a 1% GHK-Cu cream applied twice daily for 12 weeks produced statistically significant improvements in skin laxity (P<0.05), fine-line depth (P<0.03), and overall photoaging score versus vehicle [12]. Hair follicle studies are less rigorous; most positive data comes from organ-culture models rather than scalp RCTs.

Injectable GHK-Cu protocols use doses ranging from 1 to 3 mg subcutaneously or intramuscularly, typically three times per week. The plasma half-life is approximately 30 minutes after IV administration; subcutaneous half-life is not well characterized. Copper accumulation is a theoretical concern with long-term injectable use. Periodic serum copper and ceruloplasmin monitoring is advisable in anyone using injectable GHK-Cu for more than 90 days.

KPV: The Anti-Inflammatory Tripeptide

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), composed of Lys-Pro-Val. Alpha-MSH itself is a 13-amino-acid peptide that binds melanocortin receptors and suppresses NF-kB. KPV retains this NF-kB suppression in cell culture and animal models while lacking the pigmentation effects associated with the full alpha-MSH sequence, since the pigmentation-driving sequence resides in a different region of the molecule.

The most concrete mechanistic evidence comes from colitis models. A 2004 study in Journal of Pharmacology and Experimental Therapeutics showed that KPV at 1 mg/kg intraperitoneally reduced colonic TNF-alpha by 61% and IL-6 by 54% compared with vehicle in DSS-induced colitis in mice [13]. A follow-up study by the same group in 2009 demonstrated that oral KPV at 50 mcg/kg was also effective, with colitis histology scores improving by 48% versus controls [14]. The oral activity is significant because most tripeptides are rapidly cleaved by intestinal peptidases; KPV's Pro-Val C-terminus appears to confer partial resistance to those enzymes.

Human trials of KPV are limited to a small open-label feasibility study (N=10) in patients with mild-to-moderate ulcerative colitis who received oral KPV at 50 mcg twice daily for four weeks. Mean partial Mayo scores dropped from 4.2 to 2.1 (P<0.05), though the absence of a control arm limits interpretation [15]. A placebo-controlled Phase 1/2 trial is reportedly in preparation, but no ClinicalTrials.gov registration was publicly listed as of the article date.

Topical and rectal KPV formulations are also under investigation for psoriasis and inflammatory bowel disease respectively. In a murine psoriasis model, topical KPV at 0.1% reduced epidermal thickness and keratinocyte proliferation markers by approximately 35% compared with vehicle [13]. No human skin trial has been published.

Compounded oral KPV doses used in practice range from 50 to 250 mcg twice daily. Injectable protocols are less common given its oral bioavailability data, but some practitioners use 100 to 500 mcg subcutaneously for systemic anti-inflammatory indications.

How These Five Peptides Compare: Mechanism, Evidence Level, and Typical Use

Each of these compounds operates at a different biological layer, which is partly why they sometimes appear together in clinical protocols.

Larazotide works exclusively at the intestinal epithelial barrier, blocking paracellular gliadin transit. It has the most rigorous human evidence of the five, with a completed 342-patient Phase 2b RCT [2]. BPC-157 acts broadly on angiogenesis, nitric oxide signaling, and mucosal cytoprotection; its human data barely extends beyond case reports. TB-500 targets actin dynamics and cell migration, with one human RCT for corneal disease using the parent protein [9]. GHK-Cu delivers copper to metalloenzymes and triggers a coordinated matrix remodeling response, with the strongest human evidence in topical dermatology [12]. KPV suppresses NF-kB signaling in the gut mucosa and skin, with preliminary oral colitis data [14] but no completed RCT.

The table below summarizes the evidence hierarchy:

| Peptide | Best Human Evidence | Typical Compounded Dose | WADA Status | |---|---|---|---| | Larazotide | Phase 2b RCT, N=342 [2] | 0.5 mg oral three times daily | Not prohibited | | BPC-157 | Open-label pilot, N=12 [7] | 250-500 mcg SQ daily | Not explicitly listed | | TB-500 | RCT for parent protein, N=72 [9] | 2-5 mg SQ twice weekly | Prohibited (S2) | | GHK-Cu | Double-blind RCT topical, N=67 [12] | 1-3 mg SQ three times weekly | Not prohibited | | KPV | Open-label pilot, N=10 [15] | 50-250 mcg oral twice daily | Not prohibited |

Dosing, Monitoring, and Safety Considerations

No FDA-approved labeling exists for any of these peptides in the indications described here, so dosing guidance is derived from published research, compounding pharmacy protocols, and clinical experience. Starting at the lower end of any cited range and titrating based on response and tolerability is standard practice.

Before initiating injectable peptide therapy, obtain a baseline complete metabolic panel, complete blood count, high-sensitivity CRP, and (for GHK-Cu specifically) serum copper and ceruloplasmin. Repeat labs at 90 days for any protocol running longer than that window.

Injection site reactions are the most common adverse effect class across peptide therapies, occurring in an estimated 5 to 15% of users. Rotating sites and using insulin-gauge (29-31G) needles reduces both local reactions and scar tissue accumulation. Systemic allergic reactions are rare but have been reported; patients starting a new peptide should have a 20-minute observation window after the first injection.

Drug interactions are poorly characterized for all five compounds. BPC-157 may potentiate the effects of NSAIDs on gastric mucosa protection based on a 2001 rodent study [5], though the clinical relevance is unknown. No interaction data exists for larazotide, TB-500, GHK-Cu, or KPV beyond animal models. Assume interactions are possible with anticoagulants and immunomodulators until human data clarifies the picture.

Pregnancy and lactation data are absent for all five compounds. None should be used during pregnancy or while breastfeeding.

Regulatory and Legal Context

Larazotide, BPC-157, TB-500, GHK-Cu, and KPV are all available through licensed compounding pharmacies operating under CGMP standards, provided a physician writes a valid prescription for an identified patient. Bulk compounding of these agents for non-patient-specific sale is prohibited under Section 503A of the Federal Food, Drug, and Cosmetic Act [4].

The FDA issued a list in 2019 identifying certain peptides, including BPC-157, as unsuitable for use in compounding due to lack of adequate safety data. Prescribers should verify the current regulatory status of each compound with their compounding pharmacy and legal counsel before prescribing, as the FDA's position on specific peptides has shifted multiple times between 2019 and 2025 [4].

Athletes in WADA-governed sports should check each compound individually. TB-500 (and thymosin beta-4 analogues) is classified as prohibited under S2 of the WADA Prohibited List [10]. The others are not explicitly listed as of the 2025 Prohibited List, but WADA's "related substances" and "similar chemical structure" clauses could apply, and athletes should seek a formal ruling before use.